ABSTRACT: Objective: To investigate phospho-β-catenin expression in non-small cell lung cancer (NSCLC) and to study the relationship
between phospho-β-catenin expression and some clinical pathological factors. Methods: The expression of phospho-β-catenin
in 67 primary NSCLC cases detected immunohistochemically. Results: phospho-β-catenin was not expressed in normal bronchial
mucous cell and showed cytoplasmic and nuclear expression in NSCLC cell. Total positive expression rate reached 62.7%, and
positive expression rate of nucleus was 38.8%. The positive expression rate (87.5%) and nuclear expression rate of adenocarcinoma
(62.5%) were apparently higher than those of squamous cell cancer (40.0% and 17.1%) (P<0.01). Expression of phospho-β-catenin had no relationship to differentiation degree and lymphatic metastasis. The postoperative
survival time is not related to phospho-β-catenin expression. (Log-rank test, P=0.9198; P=0.6274). COX model analysis showed that tumor stage and differentiation are independent risk factors to prognosis (P=0.001; P=0.020). Conclusion: NSCLC cells show positive expression of phospho-β-catenin, phospho-β-catenin nuclear expression is relevant
to histological types. There is no difference in postoperative survival time between patients with phospho-β-catenin positive
expression and patients with negative expression, expression of phospho-β-catenin is not independent risk factor to prognosis.
Chinese Journal of Cancer Research 04/2012; 15(1):29-32. · 0.18 Impact Factor
Zhonghua bing li xue za zhi Chinese journal of pathology 01/2008; 36(12):837.
ABSTRACT: We studied the expression of axin and beta-catenin and their relation to clinicopathologic factors in 100 non-small cell lung cancers (NSCLCs) by immunohistochemical analysis. The mutation in exon 3 of the beta-catenin gene was examined by polymerase chain reaction and direct sequencing. Preserved axin expression was significantly higher in well- and moderately differentiated NSCLC samples than in poorly differentiated ones. Reduced membranous expression of beta-catenin was shown in 80 cases, whereas 26 cases had aberrant nuclear expression. Poor differentiation and lymph node metastasis were associated significantly with reduced beta-catenin expression. Lower axin expression was related significantly to higher nuclear beta-catenin expression. However, this study failed to detect any exon 3 mutation in the beta-catenin gene in the 100 NSCLC samples. We conclude that reduced beta-catenin and axin expression might predict poor differentiation in NSCLC. Reduced axin expression, but not mutation in exon 3, might be an important explanation for the abnormal beta-catenin expression in NSCLC.
American Journal of Clinical Pathology 05/2006; 125(4):534-41. · 2.60 Impact Factor
ABSTRACT: To investigate the protein expression of Axin and beta-catenin, the exon 3 mutation status of beta-catenin and their clinicopathological correlations in non-small cell lung cancer (NSCLC).
A total of 100 NSCLC samples and their corresponding normal lung tissues were obtained from the patients undergoing surgery in the First Affiliated Hospital of China Medical University between 2001 and 2003. Protein expressions of Axin and beta-catenin were detected by immunohistochemistry. DNA sequence alterations of exon 3 of beta-catenin were investigated by polymerase chain reaction (PCR) and direct sequencing.
A reduced membranous expression rate of beta-catenin was observed in 80.0% of the cases (80/100) along with a nuclear expression rate of 26.0% (26/100). There was a significant difference in beta-catenin expression between well and poorly differentiated NSCLCs. Well to moderately differentiated NSCLCs showed a reduced expression rate of 70.0% (35/50), in contrast to 90.0% (45/ 50) in poorly differentiated tumors (P = 0.012). Reduced beta-catenin expression rate was 87.3% (48/55) in cases with lymph node metastasis, in contrast to 71.1% (32/45) in cases without lymph node metastasis (P = 0.044). The positive expression rate of Axin was 48.0% (48/100). Well to moderately differentiated NSCLCs demonstrated a 60.0% positive expression rate of Axin (30/50), much higher than poorly differentiated tumors [36.0% (18/50), P = 0.016]. The positive expression rate of Axin in beta-catenin nuclear expressed NSCLCs was 15.4% (4/26), much lower than cases without beta-catenin nuclear expression [59.5% (44/74), P < 0.001]. Axin nuclear expression was found in two cases in this study, suggesting that it may function as a nuclear-cytoplasmic shuttling protein. PCR and direct sequencing failed to reveal any exon 3 mutation of beta-catenin gene.
The reduced membranous expression of beta-catenin is associated with poorly differentiated and lymph node positive NSCLCs. The expression of Axin is inversely correlated with the degree of tumor differentiation and nuclear expression of beta-catenin. The exon 3 mutations do not contribute to the abnormal protein expression of beta-catenin in NSCLCs.
Zhonghua bing li xue za zhi Chinese journal of pathology 08/2005; 34(8):519-23.
ABSTRACT: To study the expression and mutation of β-catenin in non-small cell lung cancer (NSCLC) and the relationships between expression, mutation and clinicopathological parameters and prognosis.
All the 120 samples (fixed with 10% formalin and embedded in paraffin blocks) were obtained from patients with NSCLC, who underwent surgery in the First Affiliated Hospital of China Medical University from 2001 to 2002 and Anshan Tumor Hospital from 1980 to 2001. Follow-up was available in 67 patients. The 53 fresh NSCLC samples and corresponding normal lung tissues were obtained from the First Affiliated Hospital of China Medical University. The pattern of β-catenin protein expression was detected by immunohistochemistry method (120 samples) using anti-β-catenin antibody (1:600). The level of β-catenin protein expression was detected by Western Blotting method using anti-β-catenin antibody (1:1500) in 53 fresh NSCLC samples and corresponding normal lung tissues. The mutation of β-catenin gene exon 3 was detected by polymerase chain reaction (PCR) and direct sequencing method (53 samples).
In 120 patients, abnormal expression rate of β-catenin was 80% (96/120) and nuclear expression rate was 36.7% (44/120). There was significant difference in β-catenin expression between well differentiated and poorly differentiated NSCLC. In well and moderately differentiated NSCLC cells the abnormal expression rate was 69.2% (45/65), which was much lower than 92.7% (51/55) of poorly differentiated ones (P=0.003). β-catenin expressed abnormally in 86.5% (64/74) cases with lymph node metastasis and in 69.6% (32/46) cases without lymph node metastasis (P=0.044). The results of Western Blotting showed that the expression of β-catenin in NSCLC tissues was significantly higher than that in normal lung tissues (t=2.935, P=0.005). The 53 patients' DNA were analysed by PCR and direct sequencing method, but no mutation in β-catenin gene exon 3 was found.
Abnormal expression of β-catenin is negatively associated with differentiation and positively associated with lymph node metastasis of NSCLC. The β-catenin gene exon 3 mutation is not the main reason of β-catenin abnormal expression in NSCLC.
Zhongguo fei ai za zhi = Chinese journal of lung cancer 10/2004; 7(5):409-13.
ABSTRACT: We report the morphological characteristics of 30 cases of sclerosing hemangioma (SH) of the lung and explore the histological origin of the major cells in these tumors. In addition to routine light and electron microscopy, immunohistochemistry was performed by using 12 monoclonal primary and 5 polyclonal primary antibodies. These included surfactant protein B (SP-B), thyroid transcription factor-1 (TTF-1), mast cell trypsin, CD68, epithelial antigen markers (high molecular weight cytokeratin, low molecular weight cytokeratin [CK-L], epithelial membrane antigen [EMA], cancer embryonic antigen), mesothelial antigen, neuroendocrine markers (neuron-specific enolase [NSE], chromogranin A, synaptophysin, calcitonin, adrenocorticotropic hormone, human growth hormone [hHG]), vimentin, and CD34. Surface cuboidal cells have short microvilli and have lamellar bodies in their cytoplasm. They can sometimes merge into multinuclear giant cells. Immunohistochemical results showed that these cells are strongly positive for SP-B, TTF-1, CK-L, EMA, and cancer embryonic antigen, whereas polygonal cells, previously also described as round or pale cells, were strongly positive for vimentin and TTF-1, and positive or weakly positive for 2 to 3 kinds of neuroendocrine markers. Sparse neuroendocrine granules and abundant microfilaments were observed in their cytoplasm. Some cell clusters in the solid regions were positive for SP-B and EMA. Mast cells existed sparsely in almost every field. Both cuboidal and polygonal cells were negative to CD34 and mesothelial antigen staining. We conclude that cuboidal cells of SH originate from reactive proliferating type II pneumocytes, which can fuse into multinuclear giant cells. Polygonal cells, as true tumor cells, likely originate from multipotential primitive respiratory epithelium and possess the capability for multipotential differentiation. The antibodies of SP-B, TTF-1, vimentin, and CK-L are very helpful to diagnosis and differential diagnosis of SH.
Human Pathlogy 05/2004; 35(4):503-8. · 2.88 Impact Factor
ABSTRACT: Objective: To understand the relationship between the expression of ras and p53 and histological types, degree of differentiation,
TNM classification, stage, and patients’ prognoses of non-small-cell lung cancer, we examined Ha-ras and p53 production in
143 non-small-cell lung carcinomas. Methods: One hundred and forty-three paraffin-embedded surgically resected specimens of
primary non-small-cell lung carcinomas (57 squamous cell carcinomas, 63 acinar adenocarcinomas, 15 bronchioloalveolar carcinomas,
and 8 large-cell carcinomas) were stained by streptavidin-peroxidase immunohistochemical method using anti-Ha-ras monoclonal
and anti-p53 monoclonal (DO-1) antibodies. Results: Ha-ras was found in 68% (87 of 143) of lung carcinomas. The positive rate
of Ha-ras staining in well differentiated carcinoma was 89%, significantly higher than that in moderately differentiated carcinoma
Chinese Journal of Cancer Research - CHIN J CANCER RES. 01/2004; 16(1):40-44.
ABSTRACT: To study the morphological characteristics, immunohistochemical stain and histological origin of so-called sclerosing hemangioma of the lung (S-SH), and to investigate the significance and diagnostic value of expressions of surfactant protein B (SP-B), thyroid transcription factor-1 (TTF-1) and other markers in S-SH.
Using transmission electron microscope and immunohistochemistry methods, the expressions of SP-B, TTF-1, mast cell trypsin (MCT), epithelial antigen markers (CK-H, CK-L, EMA, CEA), mesothelial antigen (MC), neuroendocrine markers (NSE, Ch-A, synaptophysin, calcitonin, ACTH, GH), vimentin and CD34 were observed in 30 cases of S-SH.
S-SH demonstrated a mixture of four histological patterns: solid, papillary, hemorrhagic and sclerotic pattern, which often showed transitional phenomena. Cuboidal cells on the surface, which contained short microvilli and lamellar bodies in cytoplasm, arranged in one row and sometimes interfused into multinuclear giant cells. Immunohistochemical results showed that these cells demonstrated strongly positive staining to SP-B, TTF-1, CK-L, EMA and CEA. The other major cell component-polygonal stromal cells were strongly positive to vimentin and TTF-1, and positive or weakly positive to 2 or 3 neuroendocrine markers in each case. Sparse neuroendocrine granulae and abundant microtubules were observed in cytoplasm of the cells. Both cuboidal and polygonal cells displayed negative immunohistochemical results to CD34 and MC. Some cell clusters in solid region were positive for SP-B and EMA. Mast cells which were positive for MCT existed sparsely in almost full vision field.
Cuboidal cells of S-SH originate from reactive proliferating type II pneumocytes and sometimes interfuse into multinuclear giant cells. The polygonal cells in stroma probably originate from multipotential primitive respiratory epithelium and have multiple differentiating ability. The presence of mast cells is also one of histological characteristics of S-SH.
Zhongguo fei ai za zhi = Chinese journal of lung cancer 04/2003; 6(2):92-6.
ABSTRACT: Objective: To investigate the expression of p120ctn in non-small-cell lung cancer (NSCLC) and its relationship with clinicopathological
factors and prognosis. Methods: p120ctn expression was tested by immunohistochemistry for 80 tumors from patients with non-small-cell
lung cancer. Correlations were investigated between p120ctn immunostaining in primary tumors and clinicopathological characteristics
and survival. Results: Abnormal expression of p120ctn was found in 68/80(85%) tumors in which 43 cases had cytoplasmic staining.
Abnormal staining of p120ctn was related with high TNM stage (P=0.003) and nodal metastasis (P=0.024). However, there was
no correlation between altered expression with poor differentiation and histological type. According to Kaplan-Meier survival
estimate, the expression of p120ctn was related to the poor survival (P=0.015) of patients. A Cox regression analysis revealed
that p120ctn expression was a significant independent factor in the prediction of survival for patients with non-small-cell
lung cancer (P=0.008). Conclusion: altered expression of p120ctn was found in non-small-cell lung cancers and was correlated
with lymph node metastasis and prognosis. From a practical point of view, the expression of p120ctn can be of prognostic value
for patients with non-small-cell lung cancer.
Chinese Journal of Cancer Research - CHIN J CANCER RES. 01/2002; 14(4):274-278.